Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a slight decline in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 20, which is higher than the peer average of approximately 15.85, and a PEG ratio of 3.01, suggesting that the stock is expensive relative to its growth prospects. Additionally, the EV to EBITDA ratio stands at 14.39, which is also above the peer average of 11.55.
In comparison to its peers, Alkermes Plc has a P/E ratio of 13.77 and an EV to EBITDA of 9.41, while ACADIA Pharmaceuticals, Inc. shows a higher P/E ratio of 19.28 but a significantly high EV to EBITDA of 33.99. This highlights that Prestige Consumer Healthcare is trading at a premium compared to some of its peers. Furthermore, the company's stock has underperformed relative to the S&P 500 over the past year, with a return of -14.12% compared to the index's 14.08%, reinforcing the notion that it may be overvalued at its current price.